An Exploration Of Candidates For Neoadjuvant Treatment In Resectable Pancreatic Cancer

Study Overview

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.

Pancreatic Cancer
Neoadjuvant

DRUG: Neoadjuvant treatment

NAT in resectable PDAC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2023-10-27	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2023-11-09
First Submitted that Met QC Criteria 2023-11-09	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2023-11-13
First Posted (ACTUAL) 2023-11-13	Results First Posted N/A	Last Verified 2023-09

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: resectable PDAC with no contact to major vessels (R-no contact)	DRUG: Neoadjuvant treatment Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
: resectable PDAC with contact PV/SMV of ≤180° (R-contact)	DRUG: Neoadjuvant treatment Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
: borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)	DRUG: Neoadjuvant treatment Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

Participant Group/Arm

Intervention/Treatment

: resectable PDAC with no contact to major vessels (R-no contact)

DRUG: Neoadjuvant treatment

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

: resectable PDAC with contact PV/SMV of ≤180° (R-contact)

DRUG: Neoadjuvant treatment

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

: borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)

DRUG: Neoadjuvant treatment

Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

Primary Outcome Measures	Measure Description	Time Frame
Overall survival	the time from diagnosis to death from any cause or the date of the last visit	From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
Between January 2007 and June 2021 at Seoul National University Hospital

Patients who had borderline resectable PDAC with arterial invasion
Patients who received chemotherapy as initial treatment and did not undergo surgery
Incomplete follow-up data for analysis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record